News

AbbVie a global biopharmaceutical company announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR...

PAREXEL International Corporation ,a leading global biopharmaceutical services provider, has been named Company of the Year – Pharmaceuticals in the 14th Annual American Business AwardsSM. The judges awarded PAREXEL a Gold Stevie® Award and recognized the...

GlaxoSmithKline plc and Innoviva, Inc announced that, following discussions with the US FDA ,GSK has brought forward the plan to file a NDA in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled...

Biogen announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the...

Expands scope of certification to include additional Otsuka Group products, reflecting the company’s improved resiliency and continuous operational capability during unexpected events. Otsuka Holdings Co Ltd is pleased to announce that its subsidiary Taiho Pharmaceutical Co.,...

Amgen announced that theCommittee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult...

Takeda Pharmaceutical Company Limited announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS® (brentuximab vedotin) and recommended its...